Califf’s close ties to the pharmaceutical industry have caused some lawmakers to question whether he would treat drug makers impartially if he is confirmed. But Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander (R-Tenn.) thinks his experience would be an asset to the agency.
The Senate HELP Committee is drafting a comprehensive bill to update the FDA’s drug approval process. Alexander says Califf’s industry perspective would help the FDA grapple with regulating medical advances as the committee figures out how to spur the process.
Read Full Article »